A study on the genetics of obesity: Influence of polymorphisms of the beta-3-adrenergic receptor and insulin receptor substrate 1 in relation to weight loss, waist to hip ratio and frequencies of common cardiovascular risk factors

Summary:

Beta-3-adrenergic receptor (beta-3-AR) and insulin receptor substrate 1 (IRS-1) have been implicated in the pathogenesis of obesity and in obesity related increase in insulin resistance which is associated with, among other diseases, dyslipidemia and type 2 diabetes mellitus. We studied 210 white female Caucasian obese subjects, who underwent a formal weight loss program (Optifast®). We examined the association between mutations of the IRS-1 gene at codon 972, mutations of the beta-3-AR gene at codon 64, and the combination of both mutations with the degree of weight loss, waist to hip ratio and the prevalence of hypertension, dyslipidemia and type 2 diabetes mellitus.

Twenty-four women (11.4%) were polymorph only for the beta-3-AR mutation, 23 women (10.9%) only for the IRS-1 mutation, and 6 subjects (2.9%) were polymorph for both alleles. No patient displayed a homozygous polymorphism. Similar frequencies of these polymorphisms were observed when the 100 non-obese control women were tested (14.0, 15.0, 3.0, respectively). After 13 weeks of weight loss the group with multiple polymorph alleles had lost less of their weight than the obese controls without mutation (Delta BMI 5.32 ± 0.18 versus 6.12 ± 0.2 kg/m², p < 0.05). In this group, the frequency of type 2 diabetes (66.7%) was significantly higher than in the obese control group without mutations (16.7%, p = 0.008).

Our findings suggest there is a synergy between the polymorphisms of Trp64Arg beta-3-AR and Gly972Arg IRS-1 in Caucasian German obese women leading to a decreased weight loss. This seems to be accompanied with an increased frequency of type 2 diabetes.

Abbreviations: beta-3-AR = beta-3-adrenergic receptor, IRS-1 = insulin receptor substrate 1, BMI = body mass index

Obesity - beta-3-adrenergic - IRS-1

References

• 1 Report of the Expert Committee on the Diagnosis and Classification of Diabetes mellitus.  Diab Care 21, Suppl. 21 S5-S19 1998; 
• 2 Almind K, Bjørbaek C, Vestergard H, Hansen T, Echwald S, Pedersen O. Aminoacid polymorphisms on insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus.  Lancet. 342 828-832 1993; 
• 3 Almid K, Inoue G, Pedersen, Kahn C R. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling.  J. Clin. Invest. 97 2569-2575 1996; 
• 4 Bouchard C, Perusse I. Genetics of obesity.  Ann. Rev. Nutr. 13 337-354 1993; 
• 5 Candelore M R, Deng L, Tota L M, Kelly L J, Cascieri M A, Strader C D. Pharmacological characterization of a recent described human beta3-adrenergic receptor mutant.  Endocrinology. 137 2638-2641 1996; 
• 6 Clausen J O, Hansen T, Bjørbaek C, Echwald S E, Urhammer S A, Rasmussen S, Andersen C B, Hansen L, Almind K, Winther K, Haraldsdòttir J, Borch-Johnsenn K, Pedersen O. Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1.  Lancet. 346 379-402 1995; 
• 7 Clement K, Ruiz J, Cassard-Coulcier A M, Bouillaud F, Ricquier D, Basdevant A, Guy-Grand B, Frougel P. Additive effect of A→G (-3826) variant of the uncoupling protein gene and the Trp64Arg mutation of the b3-adrenergic receptor gene on weight gain in morbid obesity.  Int J Obes Relat Metab Disord. 20 1062-1066 1996; 
• 8 Clement K, Vaisse C, Manning B S, Basdevant A, Guy-Grand B, Ruiz J, Silver K D, Shuldiner A R, Froguel P, Strosberg D. Genetic varaition in the beta3-adrenergic receptor and increased capacity to gain weight in patient with morbid obesity.  N. Engl. J. Med. 333 352-354 1995; 
• 9 Elbein S C, Hoffmann M, Barret K, Wegner K, Miles C, Bachman K, Berkowitz D, Shuldiner A R, Leppert M F, Hasstedt S. Role of the beta3-adrenergic receptor locus in obesity and noninsulin-dependent diabetes among members of Caucasian families with a diabetic sibling pair.  J Clin Endocrinol Metab. 81 4422-4427 1996; 
• 10 Ferranini E, Haffner S M, Mitchell B D, Stern M P. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome.  Diabetologia. 34 412-416 1991; 
• 11 Fujisawa T, Ikegami H, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Oga T, Ueda H, Shintani M, Fukuda M, Ogihara T. Association of Trp64Arg of the beta3-adrenergic receptor with NIDDM and body weight gain.  Diabetologia. 39 349-352 1996; 
• 12 Gagnon J, Mauriege P, Roy S, Sjostrom D, Chagnon Y C, Dionne F T, Oppert J M, Perusse L, Sjostrom L, Bouchard C. The Trp64Arg mutation of the beta3-adrenergic receptor gene has no effect on obesity phenotypes in the Quebec family study and Swedish obese subject cohorts.  J Clin Invets. 98 2086-2093 1996; 
• 13 Geldszus R, Mayr B, Horn R, Geisthovel F, von zur Mühlen A, Brabant G. Serum leptin and weight reduction in female obesity.  Eur. J. Endocrinol. 135 659-662 1996; 
• 14 Kadowaki H, Yasuda K, Iwamoto K, Otabe S, Shimokawa K, Silver K, Walston J, Yoshinaga H, Kosaka K, Yamada N, Saito Y, Hagura R, Akanuma Y, Shuldiner A, Yazaki Y, Kadowaki T. A mutation in the beta3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects.  Biochem Biophys Res Com. 215 555-560 1995; 
• 15 Kim-Motoyama H, Yasuda K, Yamaguchi T, Yamada N, Katakura T, Shuldiner A R, Akanuma Y, Oshashi Y, Yazaki Y, Kadowaki T . A Mutation of the beta3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride.  Diabetologia. 40 469-472 1997; 
• 16 Kissebah A H, Freedman D S, Peiris A N. Health risk of obesity.  Med. Clin. N. Amer.. 73 111-138 1989; 
• 17 Kurabayashi T, Carey D GP, Morrison N A. The beta3-adrenergic receptor gene Trp64Arg mutation is over represented in obese women: effects on weight, BMI, abdominal fat, blood pressure, and reproductive history in an elderly Australian population.  Diabetes. 45 1358-1363 1996; 
• 18 Li L S, Lonnquist F, Luthmann H, Arner P. Phenotypic characterization of the Trp64Arg polymorphism in the beta3-adrenergic receptor genen in normal eight and obese subjects.  Diabetologia. 39 857-860 1996; 
• 19 Lönnqvist F, Thörne A, Nilsell K, Hoffstedt J, Arner P. A pathogenic role of visceral fat beta3-adrenoreceptors in Obesity.  J. Clin. Invest. 95 1109-1116 1995; 
• 20 Marin P, Andersson B, Ottosson M. The morphology and metabolism of intraabdominal adipose tissue in men.  Metabolism. 41 1242-48 1992; 
• 21 Meier C A. Advances in the understanding of the molecular basis of obesity.  Eur. J. Endocrinol.. 133 761-763 1995; 
• 22 Mitchell B D, Blangero J, Comuzzie A G, Almasy L A, Shuldiner A R, Silver K, Stern M P, MacCluer J W, Hixson J E. A paired sibling analysis of the beta-3 adrenergic receptor and obesity in Mexican Americans.  J. Clin. Invest.. 101 584-587 1998; 
• 23 Moller D E, Flier J S. Insulin resistance: mechanisms, syndromes, and implications.  N. Engl. J. Med.. 325 938-948 1991; 
• 24 Nagase T, Aoki A, Yamamoto M, Yasuda H, Kado S, Nishikawa M, Kugai B, Akatsu T, Nagata N. Lack of association between the Trp64Arg mutation in the beta 3-adrenergic receptor gene and obesity in Japanese men: a longitudinal analysis.  J Clin Endocrinol Metab. 82 1284-1287 1997; 
• 25 Pietri-Rouxel F, Manning B, Gros J, Strosber A D. Eur. J. Biochem 247 1174-1179 1997; 
• 26 Rissanen J, Kuopusjarvi J, Pihlajamaki J, Sipilainen R, Heikinnen S, Vanhala M, Kekalainen P, Kuusisto J, Laakso M. The Trp64Arg polymorphism of the beta 3-adrenergic receptor gene. Lack of association with NIDDM and features of insulin resistance syndrome.  Diabetes Care. 20 1319-1323 1997; 
• 27 Sakane N, Yoshida T, Umekawa T, Kondo M, Sakai Y, Takahashi T. Beta3-adrenergic-receptor polymorphism: a genetic marker for visceral fat obesity and the insulin resistance syndrome.  Diabetologia. 40 200-204 1997; 
• 28 Sipilainen R, Uusitupa M, Heikkinen S, Rissanen A, Laakso M. Polymorphism of the beta3-adrenergic receptor gene affects basal metabolic rate in obese Finns.  Diabetes. 46 77-80 1997; 
• 29 Silver K, Braxton D M, Walston J, Sorkin J D, Stern M P, Roth J, Shuldiner A R. Trp64Arg Beta3-adrenergic receptor and obesity in Mexican Americans.  Hum Genet. 101 306-311 1997; 
• 30 Strosberg A D. Association of beta3-adrenoceptor polymorphism with obesity and diabetes: current status.  TiPS. 18 449-454 1997; 
• 31 Stunkard A J, Harris J R, Pederson N L, McClearn G E. The body mass index of twins who have been reared apart.  N. Engl. J. Med.. 322 1483-1487 1990; 
• 32 Tataranni P A, Pratley R, Shuldiner A, Ravussin E. Beta3-adrenergic receptor gene variant and lipid metabolism in Pima indians.  Diabetologia. 40 123-124 1997; 
• 33 Urhammer S A, Clausen J O, Hansen T, Pedersen O. Insulin sensitivity and body weight changes in young white carriers of the codon 64 amino acid polymorphism of the beta3-adrenergic receptor gene.  Diabetes. 45 1115-1120 1996; 
• 34 Valve R, Heikkinen S, Rissanen A, Laakso M, Uusitupa M. Synergistic effect of polymorphisms in uncoupling protein 1 and beta3-adrenergic receptor genes on basa metabolic rate in obese Finns.  Diabetologia. 41 357-361 1998; 
• 35 Walston J, Silver K, Bogardus C, Knowler W C, Celi F S, Austin S, Manning B, Strosberg A D, Stern M P, Raben N, Sorkin J D, Roth J, Shuldiner A R. Time of onset of non-insulin dependent diabetes mellitus and genetic variation in the beta3-adrenergic receptor gene.  N Engl J Med. 333 343-347 1995; 
• 36 Widen E, Lehto M, Kanninen T, Walston J, Shuldiner A R, Groop L C. Association of a polymorphism in the b3-adrenergic receptor gene with features of the insulin resistant syndrome in Finns.  N. Engl. J. Med.. 333 348-351 1995; 
• 37 Yoshihida T, Sakane N, Umekawa T, Sakai M, Takahashi T, Kondo M. Mutation of the beta3-adrenergic receptor gene and response to treatment of obesity.  Lancet. 346 1433-1434 1995; 
• 38 Zhang Y, Wat N, Stratton L M, Warren-Perry M G, Orho M, Groop L, Turner R C. UKPDS 19 heterogeneity in NIDDM: separate contributions of IRS-1 and beta3-adrenergic receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations.  Diabetologia. 39 1505-1511 1996; 

1 Statistical analysis was performed using Student's t-test (*) or using Chi-square test (**).

2 * p = 0.01, Chi-square test

3 * p < 0.05 using MANOVA compared with baseline

4 ‡ p < 0.05 using ANOVA compared with obese controls at the same time